GlassScriptPhysician profile
Misty D James
NPI 1861914921
$4,226.26
in general payments reported to CMS, 2019-2025
24 companies · $791 in 2025
The $791 reported for 2025 was more than what 81% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $154 · 2022: $575 · 2023: $1,477 · 2024: $1,229 · 2025: $791.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,316 · Education: $181.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,315.87 |
| Education | $180.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $714.11 | 2022-2025 | Xospata, Cresemba |
| Incyte Corporation | $520.41 | 2021-2025 | Jakafi, Jakafi, Niktimvo |
| Abbvie INC. | $474.75 | 2022-2024 | |
| Lilly USA, LLC | $323.37 | 2023-2025 | Jaypirca |
| Astrazeneca Pharmaceuticals LP | $282.77 | 2021-2024 | Calquence, Enhertu |
| Rigel Pharmaceuticals, INC. | $206.19 | 2023-2024 | Tavalisse, Rezlidhia |
| Sobi, INC | $185.90 | 2024-2025 | |
| Cti Biopharma Corp. | $185.78 | 2022-2023 | Vonjo |
| Novartis Pharmaceuticals Corporation | $163.55 | 2023-2025 | |
| Agios Pharmaceuticals, INC. | $137.23 | 2025 | Pyrukynd |
| Kite Pharma, INC. | $124.99 | 2024 | |
| Janssen Biotech, INC. | $124.09 | 2022-2023 | Imbruvica |
| Adaptive Biotechnologies Corporation | $117.72 | 2025 | Clonoseq |
| Daiichi Sankyo INC. | $110.89 | 2024 | Vanflyta |
| Celgene Corporation | $108.44 | 2022-2025 | Reblozyl |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beigene USA, INC. | $81.09 | 2024 | Brukinsa |
| Merck Sharp & Dohme LLC | $72.38 | 2023-2024 | Recarbrio, Dificid, Zerbaxa |
| Amgen INC. | $55.85 | 2023 | Blincyto |
| Pharmaessentia USA Corporation | $53.62 | 2023-2024 | Besremi |
| Alexion Pharmaceuticals, INC. | $49.99 | 2022 | |
| Servier Pharmaceuticals LLC | $49.60 | 2022-2023 | |
| Pharmacyclics LLC, An Abbvie Company | $31.42 | 2023 | Imbruvica |
| Syndax Pharmaceuticals, INC. | $29.01 | 2025 | |
| Taiho Oncology, INC. | $23.11 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Misty James listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.